RecruitingNot ApplicableNCT07019259

Light Therapy for Chemotherapy Induced Peripheral Neuropathy in Childhood Cancer Survivors

Sponsor

Yale University

Enrollment

20 participants

Start Date

Jun 30, 2025

Study Type

INTERVENTIONAL

Conditions

Cancer Childhood Cancer

Summary

The purpose of this study is to determine feasibility and acceptability of a six-week at-home light therapy protocol in childhood cancer survivors, to identify facilitators and barriers to implementing this intervention, and to measure signs and symptoms of Chemotherapy Induced Peripheral Neuropathy (CIPN) at baseline and following completion of the at-home light therapy protocol.

Eligibility

Min Age: 5 Years

Inclusion Criteria4

History of childhood cancer (<21 years of age at diagnosis)
Current age five years or older (due to availability of validated measures for CIPN in this age group)
History of exposure to vinca alkaloid, platinum, or other chemotherapeutic agent that can cause CIPN
CIPN as assessed by a trained physical therapist defined as a score of four or higher on the ped-mTNS (for survivors <18 years old at evaluation), or the mTNS (for survivors 18 years or older at evaluation)

Exclusion Criteria6

Currently Pregnant or lactating (by patient report, at initiation or at any point of the study)
Inability to sit still for at least 15 minutes
Diagnosis of neuropathy prior to cancer treatment
Active cancer diagnosis or cancerous skin lesion
Central nervous system tumor (due to lack of validated measures for CIPN in this population)
Cancer lesion or open wound in the area to be treated, or any condition that can potentially be made worse by the correct or incorrect use of the device.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DEVICEAnodyne Therapy System

Survivors will be provided the Anodyne Therapy System Model 120 to use as part of a 6-week at-home light therapy intervention. Participants will be instructed on where apply the device based on location of their symptoms, and will be instructed to use the device for 15 minutes per day, 3 days per week. Proper use of the device will be demonstrated in clinic by a trained physical therapist or study team member.